Study Reveals Practice Gap for Patients Undergoing Endometrial Biopsy
The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
Endometrial Cancer
Adverse Event Comparison in Patients With Cervical and Endometrial Cancer After IRMT or Standard Radiotherapy
Clinicians may be underappreciating the extent of adverse events in women with cervical and endometrial cancer who undergo radiotherapy.
Molecular Subtypes of Endometrial Clear Cell Carcinoma Appear to Have Prognostic Differences
Molecular subtypes, as indicated by the ProMisE classifier, of endometrial clear cell carcinoma are associated with different prognoses.
Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life
One finding of this study was that the mutational landscapes of normal endometrial glandular tissue were influenced by patient age and parity.
Postsurgical Mutations Detected in Cell-Free DNA in Endometrial Cancer May Indicate Poor Prognosis
In this study, pre- and postsurgical specimens of cell-free DNA from women with newly diagnosed endometrial cancer were subjected to ultra-high depth sequencing.
No OS Benefit for Addition of Metformin to Platinum-Based Therapy in Advanced Endometrial Cancer
The insulin-lowering properties of metformin, along with its effects on synthetic metabolism, were some of the rationales for its use as a cancer therapy.
Lenvatinib-Pembrolizumab Improves Outcomes in Recurrent Endometrial Cancer: KEYNOTE-146/Study 111
Lenvatinib plus pembrolizumab demonstrated promising antitumor efficacy against recurrent endometrial cancer, which led to its FDA approval.
Improved Quality of Life After Concurrent Surgery for Endometrial Cancer and Incontinence
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
TSR-042, a PD-1 Inhibitor, for Recurrent or Advanced Endometrial Cancer
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Pembrolizumab: Cost-Effective for Recurrent, MSI-H Endometrial Cancer
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
- Loading...
Loading...
Next post in SGO 2018
Loading... 
Loading...